Bio-Rad Laboratories (BIO-B)
Bio-Rad Laboratories on one page: short interest, daily short volume, fails to deliver, financials and earnings dates. Listed on NYSE, classified by the SEC as laboratory analytical instruments.
1
Short interest
settlement 2026-09-30
1.0
Days to cover
unchanged vs prior
40.0%
Short share of volume
2026-10-07
114
Fails to deliver
settlement 2020-02-18
Wed 28 Oct
Next earnings
estimated date
As of 2026-10-07.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in BIO-B is 1 share, down 1 share over the last month. Over the last 48 readings it ranged from 1 share (31 October 2024) to 220 shares (30 June 2026). The latest reading sits at the bottom of that range. At the reported average volume of 20 shares a day that is 1.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bio-b" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 1 | +100.0% | 20 | 1.00 |
| 2026-08-14 | 2 | +0.0% | 17 | 1.00 |
| 2026-07-31 | 2 | -93.5% | 12 | 1.00 |
| 2026-07-15 | 31 | -85.9% | 102 | 1.00 |
| 2026-06-30 | 220 | +21900.0% | 106 | 2.08 |
| 2026-06-15 | 1 | -98.9% | 17 | 1.00 |
| 2026-05-29 | 91 | +97.8% | 27 | 3.37 |
| 2026-05-15 | 46 | +35.3% | 490 | 1.00 |
| 2026-04-30 | 34 | +17.2% | 71 | 1.00 |
| 2026-04-15 | 29 | +11.5% | 17 | 1.71 |
| 2026-03-31 | 26 | -23.5% | 20 | 1.30 |
| 2026-03-13 | 34 | +142.9% | 51 | 1.00 |
| 2026-02-27 | 14 | +0.0% | 20 | 1.00 |
| 2026-02-13 | 14 | +0.0% | 201 | 1.00 |
| 2026-01-30 | 14 | +0.0% | 9 | 1.56 |
| 2026-01-15 | 14 | +0.0% | 10 | 1.40 |
| 2025-12-31 | 14 | -30.0% | 10 | 1.40 |
| 2025-12-15 | 20 | -13.0% | 19 | 1.05 |
| 2025-11-28 | 23 | +1050.0% | 37 | 1.00 |
| 2025-11-14 | 2 | -94.4% | 246 | 1.00 |
| 2025-10-31 | 36 | +12.5% | 77 | 1.00 |
| 2025-10-15 | 32 | +10.3% | 17 | 1.88 |
| 2025-09-30 | 29 | +20.8% | 71 | 1.00 |
| 2025-09-15 | 24 | -78.8% | 57 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 7 October 2026, the short share of BIO-B volume is 40.0%, up 6.7 points over the last five sessions. Over the last 30 readings it ranged from 0.0% (8 September 2026) to 100.0% (18 August 2026). The latest reading is 7.6 points above the 30-session average of 32.4%, on 5 shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-07 | 2 | 5 | 40.0% | 0 |
| 2026-10-06 | 0 | 1 | 0.0% | 0 |
| 2026-10-05 | 2 | 4 | 50.0% | 0 |
| 2026-10-02 | 2 | 4 | 50.0% | 0 |
| 2026-10-01 | 1 | 5 | 20.0% | 0 |
| 2026-09-28 | 1 | 3 | 33.3% | 0 |
| 2026-09-25 | 1 | 4 | 25.0% | 0 |
| 2026-09-24 | 2 | 5 | 40.0% | 0 |
| 2026-09-23 | 1 | 6 | 16.7% | 0 |
| 2026-09-22 | 0 | 1 | 0.0% | 0 |
| 2026-09-21 | 0 | 2 | 0.0% | 0 |
| 2026-09-18 | 1 | 3 | 33.3% | 0 |
| 2026-09-17 | 0 | 3 | 0.0% | 0 |
| 2026-09-16 | 0 | 1 | 0.0% | 0 |
| 2026-09-15 | 1 | 5 | 20.0% | 0 |
| 2026-09-14 | 1 | 2 | 50.0% | 0 |
| 2026-09-10 | 8 | 17 | 47.1% | 0 |
| 2026-09-09 | 1 | 25 | 4.0% | 0 |
| 2026-09-08 | 0 | 21 | 0.0% | 0 |
| 2026-09-04 | 1 | 24 | 4.2% | 0 |
| 2026-09-02 | 11 | 13 | 84.6% | 0 |
| 2026-09-01 | 6 | 9 | 66.7% | 0 |
| 2026-08-31 | 2 | 32 | 6.3% | 0 |
| 2026-08-28 | 1 | 35 | 2.9% | 0 |
| 2026-08-27 | 2 | 4 | 50.0% | 0 |
| 2026-08-25 | 1 | 1 | 100.0% | 0 |
| 2026-08-24 | 6 | 6 | 100.0% | 0 |
| 2026-08-20 | 12 | 100 | 12.0% | 0 |
| 2026-08-19 | 2 | 12 | 16.7% | 0 |
| 2026-08-18 | 1 | 1 | 100.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 18 February 2020, the fails-to-deliver balance in BIO-B is 114 shares, up 113 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (30 December 2019) to 1,900 shares (27 December 2019). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2020-02-18 | 114 | $403.48 | $46K |
| 2019-12-30 | 1 | $368.42 | $368 |
| 2019-12-27 | 1,900 | $368.80 | $701K |
| 2019-12-26 | 701 | $368.37 | $258K |
| 2019-12-24 | 702 | $369.56 | $259K |
| 2019-12-23 | 171 | $372.77 | $64K |
| 2019-12-20 | 170 | $359.61 | $61K |
| 2019-12-19 | 700 | $359.61 | $252K |
| 2019-06-21 | 5 | $306.26 | $2K |
| 2019-06-20 | 5 | $291.07 | $1K |
| 2019-05-30 | 154 | $302.00 | $47K |
| 2019-05-29 | 154 | $302.00 | $47K |
| 2018-12-31 | 157 | $226.60 | $36K |
| 2018-09-28 | 32 | $315.85 | $10K |
| 2018-08-09 | 300 | $314.40 | $94K |
| 2017-07-27 | 97 | $236.75 | $23K |
| 2017-05-05 | 1,850 | $217.70 | $403K |
| 2017-05-04 | 1,850 | $216.60 | $401K |
| 2017-05-03 | 1,850 | $221.05 | $409K |
| 2017-05-02 | 1,850 | $219.75 | $407K |
| 2017-05-01 | 1,850 | $177.85 | $329K |
| 2017-04-28 | 1,850 | $215.80 | $399K |
| 2017-04-27 | 1,850 | $213.10 | $394K |
| 2017-04-26 | 1,850 | $177.85 | $329K |
| 2016-12-19 | 75 | $157.10 | $12K |
| 2016-06-06 | 26 | $145.00 | $4K |
| 2016-05-24 | 73 | $121.50 | $9K |
| 2016-05-03 | 13 | $121.50 | $2K |
| 2016-05-02 | 13 | $121.50 | $2K |
| 2016-04-29 | 13 | $121.50 | $2K |
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Bio-Rad Laboratories reported revenue of $651.0M, down 0.1% from the same quarter a year earlier, and net income of $371.4M (13.85 diluted EPS). In FY 2025 it generated $532.2M of operating cash flow and spent $295.5M on buybacks. As of 2026-06-30, cash was $517.0M against $1.20B of debt.
- Cash
- $517.0M
- Debt
- $1.20B
- Equity
- $7.17B
- Total assets
- $10.25B
- Shares outstanding
- 27,668,031
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $651.0M | $371.4M | 57.1% | 13.85 |
| Q1 FY 2026 | 2026-03-31 | $592.1M | -$527.1M | -89.0% | -19.55 |
| Q4 FY 2025derived | 2025-12-31 | $693.2M | $720.0M | 103.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $653.0M | -$341.9M | -52.4% | -12.70 |
| Q2 FY 2025 | 2025-06-30 | $651.6M | $317.8M | 48.8% | 11.67 |
| Q1 FY 2025 | 2025-03-31 | $585.4M | $64.0M | 10.9% | 2.29 |
| Q4 FY 2024 | 2024-12-31 | n/a | -$715.8M | n/a | -25.57 |
| Q3 FY 2024 | 2024-09-30 | $649.7M | $653.2M | 100.5% | 23.34 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2.58B | $759.9M | $532.2M | $157.6M | $295.5M | n/a |
| FY 2024 | 2024-12-31 | $2.57B | -$1.84B | $455.2M | $165.6M | $203.6M | n/a |
| FY 2023 | 2023-12-31 | $2.67B | -$637.3M | $374.9M | $156.7M | $428.7M | n/a |
| FY 2022 | 2022-12-31 | $2.80B | -$3.63B | $194.4M | $112.8M | $215.7M | n/a |
| FY 2021 | 2021-12-31 | $2.92B | $4.25B | $669.5M | $133.7M | $50.0M | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2010-06-30 from the cover page.
What this page is
Bio-Rad Laboratories in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Bio-Rad Laboratories (BIO-B), SEC CIK 12208, listed on NYSE, classified by the SEC as laboratory analytical instruments. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-07.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2020-02-18.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Company record
- EDGAR filing index for CIK 12208Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as laboratory analytical instruments
Other company pages
Datasets
Frequently Asked Questions
How much of BIO-B is sold short?
What is BIO-B's daily short volume?
Does BIO-B have fails to deliver?
Are BIO-B insiders buying or selling?
What did BIO-B report last quarter?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.